Improving the health of veterans with chronic kidney disease

Not Applicable

• Conditions: Chronic kidney disease; Urological and Genital Diseases

• Registration Number: ISRCTN12374636
• Lead Sponsor: Minneapolis VA Health Care System

Brief Summary

2024 Protocol article in https://doi.org/10.1186/s12882-023-03446-1 (added 08/01/2024)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-03-15
• Last Update Posted: 4 March 2024
• Study Completion: 2026-01-01

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 4000

Inclusion Criteria

1. CKD (defined as eGFR >=25 and eGFR <60 x2)
2. Type 2 Diabetes (defined as either ICD9/10 code of Type 2 DM or most recent A1c >=7)
3. Must have active Metformin or (not on Metformin and has a Metformin allergy)

Exclusion Criteria

1. Type 1 diabetes
2. Taking SGLT-2 or GLP-1
3. SGLT2 allergy
4. On dialysis
5. Have a diagnosis of Pancreatic Cancer or Pancreatitis

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
SGLT2i initiation will be tracked quarterly by assessing the presence of SGLT2 inhibitors on active medication lists in the electronic health record

Secondary Outcome Measures

Name	Time	Method
1. Reach: Proportion of eligible patients being reached in each intervention assessed quarterly by data collected through the tracking app that has been developed to monitor patient outreach<br>2. Fidelity: Measured using an intervention tracking app assessed quarterly by data collected through the tracking app that has been developed to monitor patient outreach<br>3. Acceptability: Patient perception of starting the medication will be measured at the end of year one and the end of year two through semi-structured one-on-one qualitative interviews with patients